Priority conditions are selected on the basis of current and estimated future public health relevance, and potential for safe and cost-effective treatment.

Medically sound, cost-effective treatment for pelvic inflammatory disease and tuboovarian abscess.

In the more advanced societies pressure for cost-effective treatments, supported by evidence-based results, has come from both insurance companies and government agencies.